z-logo
open-access-imgOpen Access
RUNX3-dependent oxidative epithelial-to-mesenchymal transition in methamphetamine-induced chronic lung injury
Author(s) -
Lin Shi,
Liu BingYang,
Xin Wang,
Mei-Jia Zhu,
Lei Chen,
Miao Zhou,
Ying-Jian Gu,
Lin Cheng,
Yun Wang
Publication year - 2020
Publication title -
cell stress and chaperones
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.994
H-Index - 87
eISSN - 1466-1268
pISSN - 1355-8145
DOI - 10.1007/s12192-020-01133-w
Subject(s) - oxidative stress , epithelial–mesenchymal transition , western blot , lung , gene knockdown , reactive oxygen species , flow cytometry , chemistry , downregulation and upregulation , medicine , cancer research , pathology , andrology , immunology , apoptosis , biochemistry , gene
Lung toxicity is the main cause of the death from methamphetamine (MA) abuse, but its mechanism has remained unclear. The purpose of our study was to investigate if MA can induce epithelial-to-mesenchymal transition (EMT) and if RUNX3 is involved in oxidative EMT in MA-induced chronic lung injury. The rats were divided into the control group and MA group. Extracted lungs were used for morphological measurements and Western blot. The alveolar epithelial cells were cultured or transfected and then treated with MA or/and N-acetyl cysteine (NAC) followed by flow cytometry, Western blot, and immunohistochemistry. Chronic exposure to MA resulted in the lower growth ratio of weight, increased right ventricular index, thickened alveolar walls, and reduced number of alveolar sacs. Long-term administration with MA caused oxidative stress and pulmonary EMT. NAC increased RUNX3 and alleviated EMT. However, after knockdown of RUNX3, reactive oxygen species (ROS) levels were significantly upregulated, indicating that RUNX3 was closely related to oxidative stress. Knockdown of RUNX3 aggravated MA-induced EMT by activating RUNX3-dependent TGF-β signaling. Therefore, RUNX3 may be the key to oxidative EMT in methamphetamine-induced chronic lung injury.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here